Top

Pituitary

Published in:

01-02-2020 | Magnetic Resonance Imaging

Magnetic resonance imaging in the management of prolactinomas; a review of the evidence

Authors: Elena V. Varlamov, José Miguel Hinojosa-Amaya, Maria Fleseriu

Published in: Pituitary | Issue 1/2020

Abstract

Purpose

This review aimed to evaluate data on the use of magnetic resonance imaging in the management of prolactinomas.

Methods

Recent literature about prolactinoma behavior and magnetic resonance imaging in the management of prolactinomas is reviewed.

Results

A review of evidence regarding prolactinoma pituitary MRI follow-up; techniques and sequences, recent data on possible gadolinium retention, the role and a review of T2-weighted images in the identification of prolactinomas and frequently encountered clinical scenarios, as well as MRI correlation with prolactin secretion, tumor growth and prediction of response to medical therapy are presented.

Conclusion

The underlying decision to perform serial imaging in prolactinoma patients should be individualized on a case-by-case basis. Future studies should focus on alternative imaging methods and/or contract agents.

Eroukhmanoff J, Tejedor I, Potorac I, Cuny T, Bonneville JF, Dufour H, Weryha G, Beckers A, Touraine P, Brue T, Castinetti F (2017) MRI follow-up is unnecessary in patients with macroprolactinomas and long-term normal prolactin levels on dopamine agonist treatment. Eur J Endocrinol 176(3):323–328. https://doi.org/10.1530/EJE-16-0897 CrossRefPubMed

Bladowska J, Biel A, Zimny A, Lubkowska K, Bednarek-Tupikowska G, Sozanski T, Zaleska-Dorobisz U, Sasiadek M (2011) Are T2-weighted images more useful than T1-weighted contrast-enhanced images in assessment of postoperative sella and parasellar region? Med Sci Monit 17(10), MT83-MT90. https://doi.org/10.12659/msm.881966 CrossRefPubMedPubMedCentral

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, Wass JA, Endocrine S (2011) Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 96(2):273–288. https://doi.org/10.1210/jc.2010-1692 CrossRefPubMed

McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY (2018) Gadolinium retention: a research roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 289(2):517–534. https://doi.org/10.1148/radiol.2018181151 CrossRefPubMedPubMedCentral

Dekkers IA, Roos R, van der Molen AJ (2018) Gadolinium retention after administration of contrast agents based on linear chelators and the recommendations of the European Medicines Agency. Eur Radiol 28(4):1579–1584. https://doi.org/10.1007/s00330-017-5065-8 CrossRefPubMed

Moreno J, Vaz N, Soler J, Carrasco J, Podlipnick S (2018) High signal intensity in the dentate nucleus on unenhanced T1-weighted MR images in melanoma patients receiving macrocyclic gadolinium-based contrast. J Radiol Diagn Methods 1:101–107

Nachtigall LB, Karavitaki N, Kiseljak-Vassiliades K, Ghalib L, Fukuoka H, Syro LV, Kelly D, Fleseriu M (2019) Physicians' awareness of gadolinium retention and MRI timing practices in the longitudinal management of pituitary tumors: a "Pituitary Society" survey. Pituitary 22(1):37–45. https://doi.org/10.1007/s11102-018-0924-0 CrossRefPubMedPubMedCentral

Yuksekkaya R, Aggunlu L, Oner Y, Celik H, Akpek S, Celikyay F (2014) Assessment of t2-weighted coronal magnetic resonance images in the investigation of pituitary lesions. ISRN Radiol 2014:650926. https://doi.org/10.1155/2014/650926 CrossRefPubMedPubMedCentral

Burlacu MC, Maiter D, Duprez T, Delgrange E (2019) T2-weighted magnetic resonance imaging characterization of prolactinomas and association with their response to dopamine agonists. Endocrine 63(2):323–331. https://doi.org/10.1007/s12020-018-1765-3 CrossRefPubMed

10.

Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, Volpe R, Di Salle F, Cirillo S, Annunziato L, Lombardi G (2000) Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab 85(6):2247–2252. https://doi.org/10.1210/jcem.85.6.6657 CrossRefPubMed

11.

Lombardi M, Lupi I, Cosottini M, Rossi G, Manetti L, Raffaelli V, Sardella C, Martino E, Bogazzi F (2014) Lower prolactin levels during cabergoline treatment are associated to tumor shrinkage in prolactin secreting pituitary adenoma. Horm Metab Res 46(13):939–942. https://doi.org/10.1055/s-0034-1389925 CrossRefPubMed

12.

Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, Pivonello R, Cataldi M, Merola B, Annunziato L, Lombardi G (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579. https://doi.org/10.1210/jcem.82.11.4368 CrossRefPubMed

13.

Molitch ME (2014) Management of medically refractory prolactinoma. J Neurooncol 117(3):421–428. https://doi.org/10.1007/s11060-013-1270-8 CrossRefPubMed

14.

Akinduro OO, Lu VM, Izzo A, De Biase G, Vilanilam G, Van Gompel JJ, Bernet V, Donaldson A, Olomu O, Meyer FB, Quinones-Hinojosa A, Chaichana KL (2019) Radiographic and hormonal regression in prolactinomas: an analysis of treatment failure. World Neurosurg. https://doi.org/10.1016/j.wneu.2019.05.249 CrossRefPubMed

15.

Molitch ME, Elton RL, Blackwell RE, Caldwell B, Chang RJ, Jaffe R, Joplin G, Robbins RJ, Tyson J, Thorner MO (1985) Bromocriptine as primary therapy for prolactin-secreting macroadenomas: results of a prospective multicenter study. J Clin Endocrinol Metab 60(4):698–705. https://doi.org/10.1210/jcem-60-4-698 CrossRefPubMed

16.

Araujo C, Marques O, Almeida R, Santos MJ (2018) Macroprolactinomas: longitudinal assessment of biochemical and imaging therapeutic responses. Endocrine 62(2):470–476. https://doi.org/10.1007/s12020-018-1703-4 CrossRefPubMed

17.

Jamrozik SI, Bennet AP, James-Deidier A, Tremollieres F, Saint-Martin F, Dumoulin S, Valat-Coustols M, de Glisezinski I, Tremoulet M, Manelfe C, Louvet JP (1996) Treatment with long acting repeatable bromocriptine (Parlodel-LAR*) in patients with macroprolactinomas: long-term study in 29 patients. J Endocrinol Invest 19(7):472–479. https://doi.org/10.1007/bf03349893 CrossRefPubMed

18.

Alkabbani AG, Mon SY, Hatipoglu B, Kennedy L, Faiman C, Weil RJ, Hamrahian AH (2014) Is a stable or decreasing prolactin level in a patient with prolactinoma a surrogate marker for lack of tumor growth? Pituitary 17(2):97–102. https://doi.org/10.1007/s11102-013-0473-5 CrossRefPubMed

19.

Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P (1989) Growth of prolactinoma despite lowering of serum prolactin by bromocriptine. Neurosurgery 24(3):417–423. https://doi.org/10.1227/00006123-198903000-00020 CrossRefPubMed

20.

Saeki N, Nakamura M, Sunami K, Yamaura A (1998) Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. Endocr J 45(4):529–537. https://doi.org/10.1507/endocrj.45.529 CrossRefPubMed

21.

Schlechte JA (2007) Long-term management of prolactinomas. J Clin Endocrinol Metab 92(8):2861–2865. https://doi.org/10.1210/jc.2007-0836 CrossRefPubMed

22.

Biller BM, Luciano A, Crosignani PG, Molitch M, Olive D, Rebar R, Sanfilippo J, Webster J, Zacur H (1999) Guidelines for the diagnosis and treatment of hyperprolactinemia. J Reprod Med 44(12 Suppl):1075–1084PubMed

23.

Kharlip J, Salvatori R, Yenokyan G, Wand GS (2009) Recurrence of hyperprolactinemia after withdrawal of long-term cabergoline therapy. J Clin Endocrinol Metab 94(7):2428–2436. https://doi.org/10.1210/jc.2008-2103 CrossRefPubMedPubMedCentral

24.

Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, Di Somma C, Faggiano A, Lombardi G, Colao A (2001) Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab 86(11):5256–5261. https://doi.org/10.1210/jcem.86.11.8054 CrossRefPubMed

25.

Watanabe S, Akutsu H, Takano S, Yamamoto T, Ishikawa E, Suzuki H, Matsumura A (2017) Long-term results of cabergoline therapy for macroprolactinomas and analyses of factors associated with remission after withdrawal. Clin Endocrinol (Oxf) 86(2):207–213. https://doi.org/10.1111/cen.13240 CrossRef

26.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349(21):2023–2033. https://doi.org/10.1056/NEJMoa022657 CrossRefPubMed

27.

Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS (2005) Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas. Clin Endocrinol (Oxf) 63(1):26–31. https://doi.org/10.1111/j.1365-2265.2005.02293.x CrossRef

28.

Cannavo S, Curto L, Squadrito S, Almoto B, Vieni A, Trimarchi F (1999) Cabergoline: a first-choice treatment in patients with previously untreated prolactin-secreting pituitary adenoma. J Endocrinol Invest 22(5):354–359. https://doi.org/10.1007/BF03343573 CrossRefPubMed

29.

Passos VQ, Souza JJ, Musolino NR, Bronstein MD (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87(8):3578–3582. https://doi.org/10.1210/jcem.87.8.8722 CrossRefPubMed

30.

Molitch ME (1999) Medical treatment of prolactinomas. Endocrinol Metab Clin North Am 28(1):143–169CrossRef

31.

Orrego JJ, Chandler WF, Barkan AL (2000) Rapid re-expansion of a macroprolactinoma after early discontinuation of bromocriptine. Pituitary 3(3):189–192CrossRef

32.

Thorner MO, Perryman RL, Rogol AD, Conway BP, Macleod RM, Login IS, Morris JL (1981) Rapid changes of prolactinoma volume after withdrawal and reinstitution of bromocriptine. J Clin Endocrinol Metab 53(3):480–483. https://doi.org/10.1210/jcem-53-3-480 CrossRefPubMed

33.

March CM, Kletzky OA, Davajan V, Teal J, Weiss M, Apuzzo ML, Marrs RP, Mishell DR Jr (1981) Longitudinal evaluation of patients with untreated prolactin-secreting pituitary adenomas. Am J Obstet Gynecol 139(7):835–844. https://doi.org/10.1016/0002-9378(81)90553-6 CrossRefPubMed

34.

Schlechte J, Dolan K, Sherman B, Chapler F, Luciano A (1989) The natural history of untreated hyperprolactinemia: a prospective analysis. J Clin Endocrinol Metab 68(2):412–418. https://doi.org/10.1210/jcem-68-2-412 CrossRefPubMed

35.

Klibanski A (2010) Clinical practice Prolactinomas. N Engl J Med 362(13):1219–1226. https://doi.org/10.1056/NEJMcp0912025 CrossRefPubMed

36.

Corenblum B, Donovan L (1993) The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 59(3):671–673. https://doi.org/10.1016/s0015-0282(16)55819-1 CrossRefPubMed

37.

Testa G, Vegetti W, Motta T, Alagna F, Bianchedi D, Carlucci C, Bianchi M, Parazzini F, Crosignani PG (1998) Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 58(2):69–73CrossRef

38.

Santharam S, Fountas A, Tampourlou M, Arlt W, Ayuk J, Gittoes N, Toogood A, Karavitaki N (2018) Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal. Clin Endocrinol (Oxf) 89(3):346–353. https://doi.org/10.1111/cen.13765 CrossRef

39.

Maiter D (2019) Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109:1–9. https://doi.org/10.1159/000495775 CrossRef

40.

Lopes MBS (2017) The 2017 World Health Organization classification of tumors of the pituitary gland: a summary. Acta Neuropathol 134(4):521–535. https://doi.org/10.1007/s00401-017-1769-8 CrossRefPubMed

41.

Berezin M, Shimon I, Hadani M (1995) Prolactinoma in 53 men: clinical characteristics and modes of treatment (male prolactinoma). J Endocrinol Invest 18(6):436–441. https://doi.org/10.1007/BF03349742 CrossRefPubMed

42.

Iglesias P, Bernal C, Villabona C, Castro JC, Arrieta F, Diez JJ (2012) Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin Endocrinol (Oxf) 77(2):281–287. https://doi.org/10.1111/j.1365-2265.2012.04351.x CrossRef

43.

Delgrange E, Trouillas J, Maiter D, Donckier J, Tourniaire J (1997) Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J Clin Endocrinol Metab 82(7):2102–2107. https://doi.org/10.1210/jcem.82.7.4088 CrossRefPubMed

44.

Calle-Rodrigue RD, Giannini C, Scheithauer BW, Lloyd RV, Wollan PC, Kovacs KT, Stefaneanu L, Ebright AB, Abboud CF, Davis DH (1998) Prolactinomas in male and female patients: a comparative clinicopathologic study. Mayo Clin Proc 73(11):1046–1052. https://doi.org/10.4065/73.11.1046 CrossRefPubMed

45.

Delgrange E, Daems T, Verhelst J, Abs R, Maiter D (2009) Characterization of resistance to the prolactin-lowering effects of cabergoline in macroprolactinomas: a study in 122 patients. Eur J Endocrinol 160(5):747–752. https://doi.org/10.1530/EJE-09-0012 CrossRefPubMed

46.

Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD, Faggiano A, Biondi B, Lombardi G (2003) Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol 148(3):325–331CrossRef

47.

Pinzone JJ, Katznelson L, Danila DC, Pauler DK, Miller CS, Klibanski A (2000) Primary medical therapy of micro- and macroprolactinomas in men. J Clin Endocrinol Metab 85(9):3053–3057. https://doi.org/10.1210/jcem.85.9.6798 CrossRefPubMed

48.

Qu X, Wang M, Wang G, Han T, Mou C, Han L, Jiang M, Qu Y, Zhang M, Pang Q, Xu G (2011) Surgical outcomes and prognostic factors of transsphenoidal surgery for prolactinoma in men: a single-center experience with 87 consecutive cases. Eur J Endocrinol 164(4):499–504. https://doi.org/10.1530/EJE-10-0961 CrossRefPubMed

49.

Liu W, Zahr RS, McCartney S, Cetas JS, Dogan A, Fleseriu M (2018) Clinical outcomes in male patients with lactotroph adenomas who required pituitary surgery: a retrospective single center study. Pituitary 21(5):454–462. https://doi.org/10.1007/s11102-018-0898-y CrossRefPubMed

50.

Faje A, Chunharojrith P, Nency J, Biller BM, Swearingen B, Klibanski A (2016) Dopamine agonists can reduce cystic prolactinomas. J Clin Endocrinol Metab 101(10):3709–3715. https://doi.org/10.1210/jc.2016-2008 CrossRefPubMed

51.

Shimon I (2019) Giant prolactinomas. Neuroendocrinology 109(1):51–56. https://doi.org/10.1159/000495184 CrossRefPubMed

52.

Hamidi O, Van Gompel J, Gruber L, Kittah NE, Donegan D, Philbrick KA, Koeller KK, Erickson D, Natt N, Nippoldt TB, Young WF Jr, Bancos I (2019) Management and outcomes of giant prolactinoma: a series of 71 patients. Endocr Pract 25(4):340–352. https://doi.org/10.4158/EP-2018-0392 CrossRefPubMed

53.

Maiter D, Delgrange E (2014) Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur J Endocrinol 170(6):R213–227. https://doi.org/10.1530/EJE-14-0013 CrossRefPubMed

54.

Delgrange E, Raverot G, Bex M, Burman P, Decoudier B, Devuyst F, Feldt-Rasmussen U, Andersen M, Maiter D (2014) Giant prolactinomas in women. Eur J Endocrinol 170(1):31–38. https://doi.org/10.1530/EJE-13-0503 CrossRefPubMed

55.

Lv L, Hu Y, Yin S, Zhou P, Yang Y, Ma W, Zhang S, Wang X, Jiang S (2019) Giant prolactinomas: outcomes of multimodal treatments for 42 cases with long-term follow-up. Exp Clin Endocrinol Diabetes 127(5):295–302. https://doi.org/10.1055/a-0597-8877 CrossRefPubMed

56.

Primeau V, Raftopoulos C, Maiter D (2012) Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur J Endocrinol 166(5):779–786. https://doi.org/10.1530/EJE-11-1000 CrossRefPubMed

57.

Kreutzer J, Buslei R, Wallaschofski H, Hofmann B, Nimsky C, Fahlbusch R, Buchfelder M (2008) Operative treatment of prolactinomas: indications and results in a current consecutive series of 212 patients. Eur J Endocrinol 158(1):11–18. https://doi.org/10.1530/EJE-07-0248 CrossRefPubMed

58.

Serri O, Rasio E, Beauregard H, Hardy J, Somma M (1983) Recurrence of hyperprolactinemia after selective transsphenoidal adenomectomy in women with prolactinoma. N Engl J Med 309(5):280–283. https://doi.org/10.1056/NEJM198308043090505 CrossRefPubMed

59.

Roelfsema F, Biermasz NR, Pereira AM (2012) Clinical factors involved in the recurrence of pituitary adenomas after surgical remission: a structured review and meta-analysis. Pituitary 15(1):71–83. https://doi.org/10.1007/s11102-011-0347-7 CrossRefPubMed

60.

Schlechte JA, Sherman BM, Chapler FK, VanGilder J (1986) Long term follow-up of women with surgically treated prolactin-secreting pituitary tumors. J Clin Endocrinol Metab 62(6):1296–1301. https://doi.org/10.1210/jcem-62-6-1296 CrossRefPubMed

61.

Cohen-Inbar O, Xu Z, Schlesinger D, Vance ML, Sheehan JP (2015) Gamma Knife radiosurgery for medically and surgically refractory prolactinomas: long-term results. Pituitary 18(6):820–830. https://doi.org/10.1007/s11102-015-0658-1 CrossRefPubMed

62.

Pouratian N, Sheehan J, Jagannathan J, Laws ER Jr, Steiner L, Vance ML (2006) Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59(2):255–266. https://doi.org/10.1227/01.NEU.0000223445.22938.BD. (discussion 255–266)CrossRefPubMed

63.

Pan L, Zhang N, Wang EM, Wang BJ, Dai JZ, Cai PW (2000) Gamma knife radiosurgery as a primary treatment for prolactinomas. J Neurosurg 93(Suppl 3):10–13. https://doi.org/10.3171/jns.2000.93.supplement CrossRefPubMed

64.

Kleinberg DL, Noel GL, Frantz AG (1977) Galactorrhea: a study of 235 cases, including 48 with pituitary tumors. N Engl J Med 296(11):589–600. https://doi.org/10.1056/NEJM197703172961103 CrossRefPubMed

65.

Gillam MP, Molitch ME, Lombardi G, Colao A (2006) Advances in the treatment of prolactinomas. Endocr Rev 27(5):485–534. https://doi.org/10.1210/er.2005-9998 CrossRefPubMed

66.

Molitch ME (2006) Pituitary disorders during pregnancy. Endocrinol Metab Clin North Am 35(1):99–116. https://doi.org/10.1016/j.ecl.2005.09.011 CrossRefPubMed

67.

Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol (Oxf) 73(2):236–242. https://doi.org/10.1111/j.1365-2265.2010.03808.x CrossRef

68.

Maiter D (2016) Prolactinoma and pregnancy: from the wish of conception to lactation. Ann Endocrinol (Paris) 77(2):128–134. https://doi.org/10.1016/j.ando.2016.04.001 CrossRef

69.

Almalki MH, Ur E, Johnson M, Clarke DB, Imran SA (2012) Management of prolactinomas during pregnancy—a survey of four Canadian provinces. Clin Invest Med 35(2):E96–104CrossRef

70.

Domingue ME, Devuyst F, Alexopoulou O, Corvilain B, Maiter D (2014) Outcome of prolactinoma after pregnancy and lactation: a study on 73 patients. Clin Endocrinol (Oxf) 80(5):642–648. https://doi.org/10.1111/cen.12370 CrossRef

71.

Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, Pivonello R, Colao A (2013) Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. J Clin Endocrinol Metab 98(1):372–379. https://doi.org/10.1210/jc.2012-3039 CrossRefPubMed

72.

Bashari WA, Senanayake R, Fernandez-Pombo A, Gillett D, Koulouri O, Powlson AS, Matys T, Scoffings D, Cheow H, Mendichovszky I, Gurnell M (2019) Modern imaging of pituitary adenomas. Best Pract Res Clin Endocrinol Metab. https://doi.org/10.1016/j.beem.2019.05.002 CrossRefPubMed

73.

Hagiwara A, Inoue Y, Wakasa K, Haba T, Tashiro T, Miyamoto T (2003) Comparison of growth hormone-producing and non-growth hormone-producing pituitary adenomas: imaging characteristics and pathologic correlation. Radiology 228(2):533–538. https://doi.org/10.1148/radiol.2282020695 CrossRefPubMed

74.

Tosaka M, Sato N, Hirato J, Fujimaki H, Yamaguchi R, Kohga H, Hashimoto K, Yamada M, Mori M, Saito N, Yoshimoto Y (2007) Assessment of hemorrhage in pituitary macroadenoma by T2*-weighted gradient-echo MR imaging. AJNR Am J Neuroradiol 28(10):2023–2029. https://doi.org/10.3174/ajnr.A0692 CrossRefPubMed

75.

Puig-Domingo M, Resmini E, Gomez-Anson B, Nicolau J, Mora M, Palomera E, Marti C, Halperin I, Webb SM (2010) Magnetic resonance imaging as a predictor of response to somatostatin analogs in acromegaly after surgical failure. J Clin Endocrinol Metab 95(11):4973–4978. https://doi.org/10.1210/jc.2010-0573 CrossRefPubMed

76.

Potorac I, Petrossians P, Daly AF, Schillo F, Ben Slama C, Nagi S, Sahnoun M, Brue T, Girard N, Chanson P, Nasser G, Caron P, Bonneville F, Raverot G, Lapras V, Cotton F, Delemer B, Higel B, Boulin A, Gaillard S, Luca F, Goichot B, Dietemann JL, Beckers A, Bonneville JF (2015) Pituitary MRI characteristics in 297 acromegaly patients based on T2-weighted sequences. Endocr Relat Cancer 22(2):169–177. https://doi.org/10.1530/ERC-14-0305 CrossRefPubMed

77.

Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf) 77(1):72–78. https://doi.org/10.1111/j.1365-2265.2011.04286.x CrossRef

78.

Heck A, Emblem KE, Casar-Borota O, Ringstad G, Bollerslev J (2016) MRI T2 characteristics in somatotroph adenomas following somatostatin analog treatment in acromegaly. Endocrine 53(1):327–330. https://doi.org/10.1007/s12020-015-0816-2 CrossRefPubMed

79.

Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2016) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine 52(2):333–343. https://doi.org/10.1007/s12020-015-0766-8 CrossRefPubMed

80.

Coopmans EC, van der Lely AJ, Schneiders JJ, Neggers S (2019) Potential antitumour activity of pasireotide on pituitary tumours in acromegaly. Lancet Diabetes Endocrinol 7(6):425–426. https://doi.org/10.1016/S2213-8587(19)30113-5 CrossRefPubMed

81.

Dogansen SC, Yalin GY, Tanrikulu S, Tekin S, Nizam N, Bilgic B, Sencer S, Yarman S (2018) Clinicopathological significance of baseline T2-weighted signal intensity in functional pituitary adenomas. Pituitary 21(4):347–354. https://doi.org/10.1007/s11102-018-0877-3 CrossRefPubMed

82.

Bahuleyan B, Raghuram L, Rajshekhar V, Chacko AG (2006) To assess the ability of MRI to predict consistency of pituitary macroadenomas. Br J Neurosurg 20(5):324–326. https://doi.org/10.1080/02688690601000717 CrossRefPubMed

83.

Iuchi T, Saeki N, Tanaka M, Sunami K, Yamaura A (1998) MRI prediction of fibrous pituitary adenomas. Acta Neurochir (Wien) 140(8):779–786CrossRef

84.

Zeynalova A, Kocak B, Durmaz ES, Comunoglu N, Ozcan K, Ozcan G, Turk O, Tanriover N, Kocer N, Kizilkilic O, Islak C (2019) Preoperative evaluation of tumour consistency in pituitary macroadenomas: a machine learning-based histogram analysis on conventional T2-weighted MRI. Neuroradiology 61(7):767–774. https://doi.org/10.1007/s00234-019-02211-2 CrossRefPubMed

85.

Yiping L, Ji X, Daoying G, Bo Y (2016) Prediction of the consistency of pituitary adenoma: a comparative study on diffusion-weighted imaging and pathological results. J Neuroradiol 43(3):186–194. https://doi.org/10.1016/j.neurad.2015.09.003 CrossRefPubMed

86.

Bonneville J-F, Bonneville F, Cattin F, Nagi S (2016) MRI of the pituitary gland. Springer, SwitzerlandCrossRef

87.

Levine SN, Ishaq S, Nanda A, Wilson JD, Gonzalez-Toledo E (2013) Occurrence of extensive spherical amyloid deposits in a prolactin-secreting pituitary macroadenoma: a radiologic-pathologic correlation. Ann Diagn Pathol 17(4):361–366. https://doi.org/10.1016/j.anndiagpath.2013.03.001 CrossRefPubMed

88.

Kreutz J, Vroonen L, Cattin F, Petrossians P, Thiry A, Rostomyan L, Tshibanda L, Beckers A, Bonneville JF (2015) Intensity of prolactinoma on T2-weighted magnetic resonance imaging: towards another gender difference. Neuroradiology 57(7):679–684. https://doi.org/10.1007/s00234-015-1519-3 CrossRefPubMed

Title: Magnetic resonance imaging in the management of prolactinomas; a review of the evidence
Authors: Elena V. Varlamov
José Miguel Hinojosa-Amaya
Maria Fleseriu
Publication date: 01-02-2020
Publisher: Springer US
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Prolactinoma
Dopamine Agonist
Cabergoline
Published in: Pituitary / Issue 1/2020
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI: https://doi.org/10.1007/s11102-019-01001-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

Prolactinomas in males: any differences?

Dopamine agonist resistant prolactinomas: any alternative medical treatment?

Surgery for prolactinomas: a better choice?

Pathology of prolactinomas: any predictive value?

Prolactinomas and menopause: any changes in management?

Prolactinomas in pregnancy: considerations before conception and during pregnancy

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage